Management and outcomes of Gleason six prostate cancer detected on needle biopsy: A single-surgeon experience over 6 years

[1]  J. Oesterling,et al.  Serum prostate-specific antigen discriminates weakly between men with benign prostatic hyperplasia and patients with organ-confined prostate cancer. , 1994, European urology.

[2]  K. Stamatiou,et al.  Incidence of impalpable carcinoma of the prostate and of non‐malignant and precarcinomatous lesions in Greek male population: An autopsy study , 2006, The Prostate.

[3]  V. Reuter,et al.  Risk assessment of prostatic pathology in patients undergoing radical cystoprostatectomy. , 2008, European urology.

[4]  James A Eastham,et al.  Pathological upgrading and up staging with immediate repeat biopsy in patients eligible for active surveillance. , 2008, The Journal of urology.

[5]  T. H. van der Kwast,et al.  Is incidentally detected prostate cancer in patients undergoing radical cystoprostatectomy clinically significant? , 2009, American journal of clinical pathology.

[6]  T. Tammela,et al.  Outcomes of men with screen-detected prostate cancer eligible for active surveillance who were managed expectantly. , 2009, European urology.

[7]  Pär Stattin,et al.  Outcomes in Localized Prostate Cancer: National Prostate Cancer Register of Sweden Follow-up Study , 2010, Journal of the National Cancer Institute.

[8]  Alexandre Mamedov,et al.  Clinical results of long-term follow-up of a large, active surveillance cohort with localized prostate cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  Alan W Partin,et al.  Active Surveillance Program for Prostate Cancer: An Update of the Johns Hopkins Experience , 2011 .

[10]  M. Cooperberg,et al.  UC San Francisco UC San Francisco Previously Published Works Title Active surveillance for prostate cancer : Progress and promise , 2011 .

[11]  M. Roobol,et al.  Active surveillance for low-risk prostate cancer worldwide: the PRIAS study. , 2013, European urology.

[12]  D. Dearnaley,et al.  Medium-term outcomes of active surveillance for localised prostate cancer. , 2013, European urology.

[13]  M. Frydenberg,et al.  Psychological stress associated with active surveillance for localised low risk prostate cancer , 2013 .

[14]  M. Louie-Johnsun,et al.  Anxiety and health‐related quality of life (HRQL) in patients undergoing active surveillance of prostate cancer in an Australian centre , 2014, BJU international.

[15]  Danny Vesprini,et al.  Long-term follow-up of a large active surveillance cohort of patients with prostate cancer. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  N. Lawrentschuk.  PSA testing and early management of test‐detected prostate cancer‐ consensus at last , 2016, BJU international.

[17]  David Gillatt,et al.  10-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Localized Prostate Cancer. , 2017, The New England journal of medicine.

[18]  A. Zlotta,et al.  Stricter Active Surveillance Criteria for Prostate Cancer do Not Result in Significantly Better Outcomes: A Comparison of Contemporary Protocols. , 2016, The Journal of urology.

[19]  David C. Miller,et al.  Comparison of Pathological Outcomes for Men with Low Risk Prostate Cancer from Diverse Practice Settings: Similar Results from Immediate Prostatectomy or Initial Surveillance with Delayed Prostatectomy. , 2016, The Journal of urology.

[20]  Baris Turkbey,et al.  Magnetic Resonance Imaging‐Transrectal Ultrasound Guided Fusion Biopsy to Detect Progression in Patients with Existing Lesions on Active Surveillance for Low and Intermediate Risk Prostate Cancer , 2017, The Journal of urology.